Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 5/20 | 0.65 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GALR3 | O60755 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13545145 | 0.85 | GRN (0.67) | GRNSORT1KDM4EMAPTGALR3 | |
| SCHEMBL350610 | 0.85 | GRN (0.67) | GRNSORT1KDM4EMAPTGALR3 | |
| SCHEMBL352154 | 0.85 | GRN (0.67) | GRNSORT1KDM4EMAPTGALR3 | |
| SCHEMBL352072 | 0.81 | GRN (0.71) | GRNSORT1KDM4EMAPTGALR3 | |
| SCHEMBL350954 | 0.80 | KDM4E (0.65) | GRNSORT1KDM4EMAPTGALR3 | |
| SCHEMBL8260077 | 0.79 | GRN (0.73) | GRNSORT1KDM4EMAPTGALR3 | |
| SCHEMBL1572486 | 0.79 | GRN (1.00) | GRNSORT1KDM4EMAPTGALR3 | |
| SCHEMBL24927900 | 0.77 | SMN1; SMN2 (0.42) | GRNSORT1KDM4EMAPTLMNA | |
| SCHEMBL350765 | 0.77 | GRN (0.71) | GRNSORT1KDM4EMAPTGALR3 | |
| SCHEMBL12868385 | 0.77 | GRN (0.71) | GRNSORT1KDM4EMAPTGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, TRPV1 | GRN 4810/4885SORT1 2723/4885KDM4E 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.